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A B S T R A C T
In 2007 the European Society of Hypertension, the American Heart Association and 
the International Society of Hypertension-World Health Organization published new 
guidelines for the management of hypertension. According to these new guidelines, 
drug treatment is recommended in all subjects with consistent elevation of blood pres-
sure above 140 mmHg systolic and/or 90 mmHg diastolic. In high-risk subjects, treat-
ment initiation is indicated in lower blood pressure levels (systolic above 130 mmHg 
and/or diastolic above 85 mmHg). The higher the blood pressure level the sooner the 
treatment is commenced, with emphasis being placed on the critical role of combina-
tion pharmacotherapy in order to achieve optimal blood pressure control.. The imple-
mentation of the new guidelines is expected to achieve more effective cardiovascular 
protection in hypertensive patients.
I N T R O D U C T I O N
In 2007 the European Society of Hypertension, the American Heart Association 
and the International Society of Hypertension-World Health Organization published 
new guidelines for the management of hypertension.1-3 The need of developing new 
guidelines for hypertension is due to recently published research data suggesting 
important modifications in the diagnostic and therapeutic strategies in clinical prac-
tice. The implementation of the new guidelines is expected to achieve more effective 
cardiovascular protection in hypertensive patients.
T O T A l  C A R D I O vA S C U l A R  R I S k  A S S e S S m e N T  I N  D e C I S I O N 
m A k I N g
The European as well as the American guidelines of 2007 in general proposed more 
aggressive approaches compared to previous guidelines, regarding treatment initiation 
and also blood pressure goals.1-3 In both guidelines the intervention strategy is decided 
on the basis of total cardiovascular risk assessment. High risk hypertensive patients 
are regarded as those with (a) stage III hypertension, (b) asymptomatic target organ 
damage (left ventricular hypertrophy, microalbuminuria, atherosclerosis of carotid 
arteries), (c) diabetes mellitus, (d) at least three additional cardiovascular risk factors 
(e.g. metabolic syndrome), or (e) established cardiovascular disease (coronary heart 
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disease, stroke or transient ischemic attack, renal insufficiency 
or proteinuria, intermittent claudication, aortic aneurysm).
T R e A T m e N T  I N I T I A T I O N
According to the new guidelines, drug treatment is 
recommended in all subjects with consistent elevation of 
blood pressure above 140 mmHg systolic and/or 90 mmHg 
diastolic. In all subjects with high total cardiovascular risk, 
treatment initiation is indicated in lower blood pressure levels 
(systolic above 130 mmHg and/or diastolic above 85 mmHg). 
The higher the blood pressure level the shorter should be 
the duration of observation before treatment initiation. In 
high-risk hypertensives prompt drug treatment initiation is 
recommended, whereas in those at low risk a period of obser-
vation by applying non-pharmacological measures (lifestyle 
modification) for up to 1-12 months (according to the level of 
total risk) might be allowed.
B l O O D  p R e S S U R e  g O A l
In hypertensive subjects with low total cardiovascular 
risk, the goal of treatment is to reduce office blood pressure 
below 140 mmHg systolic and 90 mmHg diastolic and even 
lower if treatment is well tolerated (as it is the case in most 
patients). In all high-risk hypertensives the goal of treatment 
is lower (systolic below 130 mmHg and diastolic 80 mmHg). 
Reaching optimal blood pressure control is essential in order 
to achieve effective protection from cardiovascular events. 
Inadequate blood pressure control is associated with lesser 
cardiovascular protection.
F I R S T  l I N e  A N T I h y p e R T e N S I v e  D R U g S
The primary criterion for choosing antihypertensive drugs 
is their proven ability to prevent cardiovascular morbidity and 
mortality in large outcome trials. In the recent American, 
International and British hypertension guidelines four classes 
of drugs are recommended as first line treatment of hyper-
tension: thiazide diuretics, angiotensin converting enzyme 
inhibitors (ACEIs), angiotensin receptor blockers (ARBs) 
and calcium channel blockers (CCBs).2-4
Traditional cardiovascular drugs such as beta-blockers 
are no longer recommended as first line treatment in hyper-
tension, unless there is a specific indication (e.g. myocardial 
infarction or heart failure). The European guidelines made a 
more conservative statement for beta-blockers focusing on the 
negative metabolic effects of these drugs.1 According to the 
European guidelines beta-blockers remain a first line choice 
for the treatment of hypertension. However, these drugs, 
and particularly their combination with diuretics, should be 
avoided in hypertensive patients with metabolic syndrome or 
with high risk of developing diabetes mellitus, unless there is 
a specific indication for their use.
C O m B I N A T I O N  A N T I h y p e R T e N S I v e 
p h A R m A C O T h e R A p y
Using antihypertensive drug monotherapy the recom-
mended blood pressure goals can be reached in fewer than 
50% of hypertensive patients. In most cases combination of 
2-3 and often more drugs is needed. This is particularly true 
in high-risk hypertensives, who have more difficult to control 
hypertension and also lower treatment target.
In the new guidelines emphasis has been placed in the 
critical role of combination pharmacotherapy in order to 
achieve optimal blood pressure control. The rationale for 
combining drugs is to achieve larger reduction in blood 
pressure. The additional antihypertensive effect is larger for 
some drug combinations and weaker for others. Combina-
tion of drugs with different and complementary mechanisms 
of action provide strong synergistic blood pressure lowering 
effect (e.g. renin angiotensin system blockers combined with 
diuretics or CCBs). On the other hand, drugs sharing com-
mon mechanisms of action provide smaller additional blood 
pressure lowering effect (e.g. ACEIs combined with ARBs or 
beta-blockers). However, the primary criterion for choosing 
drug combinations should be their proven ability to provide 
long-term cardiovascular protection.
An additional benefit obtained by the appropriate selec-
tion of antihypertensive drug combinations is the potential to 
reduce the incidence of adverse effects of the drugs. In other 
words, the addition of a second drug might reduce the adverse 
effects of the first one, or the reverse. For example, ACEIs 
and ARBs reduced the incidence of hypokalemia induced 
by diuretics and also the ankle edema induced by CCBs. In 
addition, beta-blockers attenuate the tachycardia induced by 
dihydropiridine CCBs and diuretics attenuate the counteregu-
latory sodium retention induced by all vasodilatory drugs.
In most cases treatment initiation with monotherapy is 
indicated. According to the American and the European hy-
pertension guidelines, treatment initiation with a combination 
of two drugs should be considered when there is a consistent 
rise in blood pressure of more than 20 mmHg systolic and/or 
10 mmHg diastolic above the recommended goal, particularly 
in subjects with high total cardiovascular risk.
The use of fixed-dose combinations is a very popular ther-
apy in hypertension. Many fixed-dose combinations of ACEIs 
or ARBs with thiazide diuretics (mostly hydrochlorothiazide) 
are available and widely used. Apart from the strong additive 
antihypertensive effect provided by these combinations, it 
should be remembered that the vast majority of the outcome 
trials that assessed the efficacy of ACEIs and ARBs in im-
proving prognosis have used these drugs in combination with 
thiazide diuretics. The combination of CCBs with thiazide 
diuretics also gives strong additional antihypertensive effect 
and is an evidence-based choice on the basis of an outcome 
study data (VALUE).5 On the other hand, the combination 
of a beta-blocker with a thiazide diuretic should be avoided if 
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possible, particularly in subjects at increased risk of diabetes 
development.
In the 2007 guidelines of the American Heart Associa-
tion (AHA) - American Diabetes Association (ADA) for the 
management of hypertension in diabetic patients and the 2007 
guidelines of the US National Kidney Foundation KDOQI 
Clinical Practice Guidelines for the management of diabetic 
hypertensives with renal damage, it is recommended that 
antihypertensive drug treatment should be initiated with 
ACEIs or ARBs with the addition of a diuretic as a second 
drug in most cases.-8
The first fixed-dose combination of an ARB with a CCB 
has recently become available on the market and several 
similar combinations are expected to follow in the future. This 
combination also offers strong additional antihypertensive 
effect and has a potential metabolic advantage compared 
to diuretic based combinations, particularly in subjects 
with pre-diabetes or metabolic syndrome.9,10 An outcome 
study (ACCOMPLISH) providing a direct comparison of a 
combination of an ACEI with a dihydropiridine CCB versus 
an ACEI-diuretic combination in high risk hypertensives is 
expected to report its final results in 2008.11
The combination of an ACEI with an ARB remains con-
troversial. This combination provides substantial additional 
antihypertensive effect, but lower than that obtained when 
each of these drugs is combined with a thiazide diuretic or a 
CCB. The long-term cardiovascular effects of this combina-
tion are still under investigation. There is evidence that this 
combination provides significant additional antiproteinuric 
effect in patients with diabetic or non-diabetic nephropathy 
and proteinuria. Furthermore, outcome studies in heart 
failure showed additional cardiovascular protection with 
this combination compared with ACEIs alone. On the other 
hand, one large outcome study in subjects post-myocardial 
infarction with heart failure showed no additional benefit 
with the ACEI-ARB combination compared to each of the 
monotherapies. The use of this combination in patients with 
heart failure requires close monitoring of blood pressure, 
serum creatinine and potassium. A large outcome study 
(ONTARGET) comparing an ACEI (ramipril) (n= 857) 
with an ARB (telmisartan) (n=8542) and their combination 
(n=8502) in the prevention of cardiovascular events in high 
risk patients was just published.12,13 It reported that the ARB 
was equivalent to the ACEI in patients with vascular disease 
or high risk diabetes and was associated with less angioedema. 
The combination of the two drugs was associated with more 
adverse events without an increase in benefit.
In a substantial proportion of hypertensive patients, the 
recommended blood pressure goal is not achieved despite 
the use of two drugs. The most popular triple combination 
is a renin-angiotensin blocker with a thiazide diuretic and a 
CCB.14 In most cases triple antihypertensive drug therapy can 
be administered altogether in the morning, provided that long-
acting drugs with full 24-hour coverage are used. If needed, 
more drugs might be added, with preference in first line drugs, 
often at higher than usual dosing and some of the drugs might 
be administered before night-time sleep. Patients with resist-
ant hypertension should be referred to a special hypertension 
clinic for further investigation and management.
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